- Home
- LOMA vs NRIX Comparison
LOMA vs NRIX Comparison
Compare LOMA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOMA
- NRIX
- Stock Information
- Founded
- LOMA 1926
- NRIX 2009
- Country
- LOMA Argentina
- NRIX United States
- Employees
- LOMA N/A
- NRIX N/A
- Industry
- LOMA Building Materials
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- LOMA Industrials
- NRIX Health Care
- Exchange
- LOMA Nasdaq
- NRIX Nasdaq
- Market Cap
- LOMA 1.5B
- NRIX 1.4B
- IPO Year
- LOMA 2017
- NRIX 2020
- Fundamental
- Price
- LOMA $12.31
- NRIX $19.28
- Analyst Decision
- LOMA Sell
- NRIX Strong Buy
- Analyst Count
- LOMA 2
- NRIX 17
- Target Price
- LOMA $6.55
- NRIX $31.06
- AVG Volume (30 Days)
- LOMA 488.5K
- NRIX 655.6K
- Earning Date
- LOMA 03-05-2025
- NRIX 01-28-2025
- Dividend Yield
- LOMA N/A
- NRIX N/A
- EPS Growth
- LOMA N/A
- NRIX N/A
- EPS
- LOMA 0.63
- NRIX N/A
- Revenue
- LOMA $265,542,171.00
- NRIX $54,549,000.00
- Revenue This Year
- LOMA N/A
- NRIX $5.98
- Revenue Next Year
- LOMA N/A
- NRIX $9.50
- P/E Ratio
- LOMA $18.88
- NRIX N/A
- Revenue Growth
- LOMA N/A
- NRIX N/A
- 52 Week Low
- LOMA $5.70
- NRIX $8.11
- 52 Week High
- LOMA $13.79
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- LOMA 53.60
- NRIX 42.84
- Support Level
- LOMA $11.50
- NRIX $19.24
- Resistance Level
- LOMA $12.54
- NRIX $20.50
- Average True Range (ATR)
- LOMA 0.57
- NRIX 1.00
- MACD
- LOMA 0.06
- NRIX 0.08
- Stochastic Oscillator
- LOMA 78.67
- NRIX 24.67
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue Derives from Cement, masonry cement, and lime segment.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.